[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.136.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
JAMA Cardiology Clinical Guidelines Synopsis
March 2017

Ongoing Management of Patients With Supraventricular Tachycardia

Author Affiliations
  • 1Division of Cardiology and Duke Clinical Research Institute, Duke University Hospital, Durham, North Carolina
  • 2Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison
JAMA Cardiol. 2017;2(3):332-333. doi:10.1001/jamacardio.2016.5085

Supraventricular tachycardia (SVT) is frequently encountered by health care clinicans.1,2 Therefore, it is imperative for clinicians to recognize the clinical manifestations of SVT and choose the best test to establish a diagnosis. Available tests include a Holter monitor (if symptoms occur daily or every other day), ambulatory electrocardiographic monitoring (if symptoms occur weekly or biweekly), or an implantable loop recorder (if symptoms are infrequent or a diagnosis could not be established with noninvasive monitoring despite ongoing symptoms). Long-term management of SVT includes pharmacologic therapy, catheter ablation, or observation. The selection of long-term treatment depends on several factors, including the frequency and severity of the patient’s symptoms, the presence of structural heart disease, the presence of noncardiac comorbidities, and the patient’s preferences.1,2

×